[06/11]美国华人生物医药科技协会（CBA）第二十一届年会
 Biopharm US-China: Accelerating Global Development and Commercialization through Partnership
Saturday, June 11, 2016 Wayne T. Hockmeyer Auditorium MedImmune, A Member of the AstraZeneca Group 1 MedImmune Way, Gaithersburg, MD 20878 此次年会的主题是：中美生物制药： 1. 创新医药研发及商业化 2. 肿瘤免疫治疗和联合用药 3. 精准医疗,生物标记及数字医疗 4. 生物仿制药 5. CBA-MedImmune: 6. 分组讨论:涉及中美法律，法规及创业方面的相关问题 这次会议为来自政府机构，私企， 除了扣人心弦的大会议程外，CBA还会在大会中颁发杰出贡献奖，
Preliminary Program:
7:30 AM – 8:30 AM Registration and Continental Breakfast; Exhibition Booth Setup 8:30 AM – 8:35 AM Welcome to the 21st CBA Annual Conference Xu-Rong Jiang,M.D., Ph.D., President-elect of CBA 8:35AM– 8:45 AM Opening Remarks Minister Xi Wu,Embassy of the People’s Republic of China in the USA 8:45AM– 8:55 AM Opening Remarks Mr. John C. Wobensmith, Maryland State of Secretary 8:55AM – 9:00 AM Introduction of the CBA Brilliant Achievement Awardees Shou-Bai Chao,Ph.D., President of CBA 9:00AM– 9:30 AM Brilliant Achievement Award Presentations Bahija Jallal, Ph.D., EVP of AstraZeneca, Head of MedImmune, A Member of the AstraZeneca Group 9:30AM– 10:00 AM Ge Li, Ph.D., CEO and Chairman of Board of Directors, WuXi AppTec 10:00AM– 10:15 AM Break and Refreshments 10:15AM– 11:30 AM Session 1: Regulatory Challenges and Opportunities in China and US Session Chair and Co-chair: Dan Zhang, M.D., President & CEO, Fountain Medical Development Ltd, and Qiao Bobo, Ph.D., Review and Inspection Officer, FDA 10:15AM – 10:35 AM Marjorie Shapiro, Ph.D.,Chief, Laboratory of Molecular and Developmental Immunology, Division of Biotechnology Products Research and Review I, OBP/OPQ/CDER/FDA 10:35 AM – 10:55 AM Yi Feng, Ph.D., former Assistant to the Director-General of the CDE of CFDA 10:55 AM – 11:15 AM Regulatory Considerations on Molecular In Vitro Diagnostics Yun-Fu Hu, Ph.D., Associate Director, Division of Immunology and Hematology Devices, Office of In Vitro Diagnostic Device Evaluation and Safety, CDRH, FDA 11:15AM– 11:35 AM Regulatory Considerations for Global Biologics Development John Finkbohner, Ph.D., Senior Director, US RA, MedImmune 11:35AM– 11:50 AM Session 1 Panel Discussion 11:50PM – 12:45PM Session 2: Immune-oncology and Cell Therapy Session Chair and Co-chair: Yingxian Xiao, Ph.D., President & CEO, Potomac Pharmaceuticals, Inc., and Yuling Li, Ph.D., Scientific Director, MedImmune 11:50 PM – 12:10 PM Tony Ho, M.D., VP of Immuno-Oncology, AstraZeneca 12:10 PM – 12:30 PM Cell therapy speaker TBD (Linda Powers’s company?) 12:30PM – 12:45PM Session 2 Panel Discussion Panelist: Tony Ho, Linda Liu, Linda Powers
12:45 – 1:45 PM Luncheon & Sponsor Presentations Session Chairs: Min Zhu, Ph.D., Principal Scientist, MedImmune, andKun Yao, Ph.D., Director, AstraZeneca Afternoon Sessions 1:45PM –3:00 PM Session 3: Global Collaboration Session Chair and Co-chair: Jarrod Borkat, Ph.D., Sr. Director, MedImmune, and Ziping Wei,Ph.D., Executive Director, Novavax, Inc. 1:45 PM – 2:05 PM Jarrod Borkat, PhD, Sr. Director, Head of External Collaboration, MedImmune 2:05 PM – 2:25 PM Guozhong Rui, Ph.D., Director, China Pharmtech Transfer Center 2:25 PM – 2:45 PM Youling Wu, Ph.D., CEO, Teruisi Pharmaceuticals 2:45 PM – 3:00 PM Session 3 Panel Discussion 3:00PM – 3:15 PM Break and Refreshments 3:15 PM – 4:30 PM Session 4: Biomarkers, Translational Research andPrecision Medicine Session Chair and Co-chair: Richard Zhao, Ph.D., Professor, University of Maryland School of Medicine, and Zhifeng Long, Ph.D., President, Personal Diagnostix 3:15 PM – 3:35 PM Molecular Baseline to Manage Person Health Guo-Liang Yu, Ph.D., Chairman of Board, Quantum Health Corporation 3:35 PM –3:55 PM Laura Richman, Ph.D., Ex-VP, MedImmune 3:55 PM – 4:15 PM Dr. Wei Zhou, CEO of Centrillion 4:15PM – 4:30 PM Session 4 Panel Discussion 4:30 PM – 5:10 PM Session 5: What Scientists and Entrepreneurs in US Should Know Session Chair and Co-chair: Ching-JeyGeorge Chang, Ph.D.,Senior Pharmacologist, CDER, FDA, Steve Chen, J.D., Ph.D., Patent Counsel, DSM Nutritional Products LLC. 4:30 PM – 4:55 PM Brian Sun, Committee 100 4:55 PM – 5:10 PM Session 5 Panel Discussion Panelists: Brian Su, Kening Li, Lin Sun-Hoffman 5:10 – 6:10 PM Session 6 CBA-SCBA Joint Session- Cancer Therapeutics Session Chair and Co-chair: Li Yang, Ph.D.,Senior Investigator& Head, Tumor Microenvironment Section, Laboratory of Cancer Biology and Genetics, NCI, Mitchell Ho, Ph.D.,Senior Investigator, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, NCI 5:10 PM – 5:25 PM Targeting Myeloid TGF-beta Signaling in Cancer Metastasis Li Yang, Ph.D., Senior Investigator& Head, Tumor Microenvironment Section, Laboratory of Cancer Biology and Genetics, NCI 5:25 PM – 5:40 PM Rationalize Target Combination in Cancer Cells Ji Luo Ph.D., Head, Cancer Systems Biology Section, Laboratory of CancerBiology and Genetics (LCBG), NCI 5:40 PM – 5:55 PM Novel Antibodies Target Cancer Signaling Mitchell Ho, Ph.D., Senior Investigator, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, NCI 5:55 PM – 6:10 PM Session 6 Panel Discussion 6:10 PM Exhibitors take down their booths and get ready for the Reception
21st CBA Annual Conference Reception and Dinner, MedImmune Cafeteria 2016 CBA Outstanding Service Award and Presentation 2016 CBA President-Elect (2016-2017) Election Announcement 2016 CBA President-Elect (2016-2017) Statement |
